Evidence map›Paper›PMID 23333453›Full record

ArticleBrain research2013

An update on the cognitive impact of clinically-used hormone therapies in the female rat: models, mazes, and mechanisms.

J I Acosta, R Hiroi, B W Camp, J S Talboom, H A Bimonte-Nelson

Abstract read
In one paragraph

Article in Brain research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Review
  3. From Menopause to Neurodegeneration-Molecular Basis and Potential Therapy.International journal of molecular sciences · 2021
    Review
  4. Review
  5. Estradiol Protects White Matter of Male C57BL6J Mice against Experimental Chronic Cerebral Hypoperfusion.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2018
    Article
  6. Review
  7. Sex and post-menopause hormone therapy effects on hippocampal volume and verbal memory.Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition · 2017
    Article
  8. Effect of Ovarian Hormone Therapy on Cognition in the Aged Female Rhesus Macaque.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

J I AcostaDepartment of Psychology, Arizona State University, Tempe, AZ 85287, USA.
R Hiroi
B W Camp
J S Talboom
H A Bimonte-Nelson
Arizona Alzheimer’s ConsortiumAlzheimer's Association · USArizona State University · US

Funding

Variations in Hormone Therapy: Effects on Cognition and Markers of Brain AgingR01AG028084 · NIA · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI BIMONTE-NELSON, HEATHER ALLYSON · 2007 to 2022
$4.7M
Regulation of the Tryptophan Hydroxylase-2 Promoter by EstrogenF32MH093145 · NIMH · UNIVERSITY OF ARIZONA · PI HIROI, RYOKO · 2011 to 2013
$166k
NIA NIH HHS R01 AG028084NIMH NIH HHS F32 MH093145
6 · The paper itself

Abstract

In women, ovarian hormone loss associated with menopause has been related to cognitive decline. Hormone therapy (HT) may ameliorate some of these changes. Understanding the cognitive impact of female steroids, including estrogens, progestogens, and androgens, is key to discovering treatments that promote brain health in women. The preclinical literature has presented elegant and methodical experiments allowing a better understanding of parameters driving the cognitive consequences of ovarian hormone loss and HT. Animal models have been a valuable tool in this regard, and will be vital to future discoveries. Here, we provide an update on the literature evaluating the impact of female steroid hormones on cognition, and the putative mechanisms mediating these effects. We focus on preclinical work that was done with an eye toward clinical realities. Parameters that govern the cognitive efficacy of HT, from what we know thus far, include but are not limited to: type, dose, duration, and route of HT, age at HT initiation, timing of HT relative to ovarian hormone loss, memory type examined, menopause history, and hormone receptor status. Researchers have identified intricate relationships between some of these factors by studying their individual effects on cognition. As of late, there is increased focus on studying interactions between these variables as well as multiple hormone types when administered concomitantly. This is key to translating preclinical data to the clinic, wherein women typically have concurrent exposure to endogenous ovarian hormones as well as exogenous combination HTs, which include both estrogens and progestins. Gains in understanding the parameters of HT effects on cognition provide exciting novel avenues that can inform clinical treatments, eventually expanding the window of opportunity to optimally enhance cognition and brain health in aging women. This article is part of a Special Issue entitled Hormone Therapy.

Indexed as

AgingAnimalsBrainCognition DisordersDisease Models, AnimalDrug Evaluation, PreclinicalEstrogen Replacement TherapyFemaleMaze LearningRatsSteroidsSteroids

Identifiers

PMID23333453
PMCPMC3739440
OpenAlexW2058267721

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.